{
  "metadata": {
    "analysis_date": "2026-02-07",
    "protocol": "Fuzzy-to-Fact (6-Phase)",
    "query": "Doxorubicin resistance mechanisms and clinical outcome correlations",
    "databases_accessed": 12,
    "clinical_trials_analyzed": 40,
    "confidence_level": "HIGH",
    "evidence_grade": "L3-L4"
  },
  "nodes": [
    {
      "id": "CHEMBL:53463",
      "type": "ChemicalCompound",
      "name": "Doxorubicin",
      "aliases": ["Adriamycin", "Adriablastin", "Hydroxydaunorubicin"],
      "molecular_formula": "C27H29NO11",
      "molecular_weight": 543.53,
      "max_phase": 4,
      "cross_references": {
        "chembl": "CHEMBL:53463",
        "pubchem": "PubChem:CID31703"
      },
      "mechanism": "Anthracycline antibiotic that intercalates DNA and stabilizes topoisomerase II-DNA cleavage complexes",
      "indications_count": 109
    },
    {
      "id": "HGNC:40",
      "type": "Gene",
      "symbol": "ABCB1",
      "name": "ATP binding cassette subfamily B member 1",
      "aliases": ["MDR1", "P-gp", "CD243", "GP170"],
      "location": "7q21.12",
      "cross_references": {
        "hgnc": "HGNC:40",
        "ensembl": "ENSG00000085563",
        "uniprot": "UniProtKB:P08183",
        "entrez": "5243",
        "string": "STRING:9606.ENSP00000478255"
      },
      "function": "Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells",
      "resistance_mechanism": "Drug efflux (reduces intracellular doxorubicin concentration)"
    },
    {
      "id": "HGNC:990",
      "type": "Gene",
      "symbol": "BCL2",
      "name": "BCL2 apoptosis regulator",
      "aliases": ["Bcl-2", "PPP1R50"],
      "location": "18q21.33",
      "cross_references": {
        "hgnc": "HGNC:990",
        "ensembl": "ENSG00000171791",
        "uniprot": "UniProtKB:P10415",
        "entrez": "596",
        "string": "STRING:9606.ENSP00000381185"
      },
      "function": "Suppresses apoptosis by controlling mitochondrial membrane permeability; inhibits caspase activity",
      "resistance_mechanism": "Apoptosis evasion (prevents doxorubicin-induced cell death)"
    },
    {
      "id": "HGNC:11998",
      "type": "Gene",
      "symbol": "TP53",
      "name": "tumor protein p53",
      "aliases": ["p53", "LFS1"],
      "location": "17p13.1",
      "cross_references": {
        "hgnc": "HGNC:11998",
        "ensembl": "ENSG00000141510",
        "uniprot": "UniProtKB:P04637",
        "entrez": "7157",
        "string": "STRING:9606.ENSP00000269305"
      },
      "function": "Tumor suppressor inducing cell cycle arrest, DNA repair, or apoptosis upon DNA damage",
      "resistance_mechanism": "Loss of apoptosis signaling (mutations abolish p53-mediated response to DNA damage)"
    },
    {
      "id": "HGNC:11989",
      "type": "Gene",
      "symbol": "TOP2A",
      "name": "DNA topoisomerase II alpha",
      "aliases": ["TOP2alpha", "TOPIIA"],
      "location": "17q21.2",
      "cross_references": {
        "hgnc": "HGNC:11989",
        "ensembl": "ENSG00000131747",
        "uniprot": "UniProtKB:P11388",
        "entrez": "7153",
        "string": "STRING:9606.ENSP00000411532"
      },
      "function": "Decatenating enzyme that alters DNA topology by transient double-strand breaks",
      "resistance_mechanism": "Reduced drug target (downregulation or mutations reduce doxorubicin binding)"
    },
    {
      "id": "CHEMBL:3137309",
      "type": "ChemicalCompound",
      "name": "Venetoclax",
      "mechanism": "BCL2 inhibitor",
      "cross_references": {
        "chembl": "CHEMBL:3137309",
        "iuphar": "IUPHAR:8318"
      },
      "fda_approved": true,
      "indication": "Chronic lymphocytic leukemia, acute myeloid leukemia"
    },
    {
      "id": "CHEMBL:6966",
      "type": "ChemicalCompound",
      "name": "Verapamil",
      "mechanism": "Calcium channel blocker; P-glycoprotein inhibitor (first-generation)",
      "cross_references": {
        "chembl": "CHEMBL:6966",
        "iuphar": "IUPHAR:2406"
      },
      "fda_approved": true,
      "limitation": "Cardiac side effects limit use as P-gp inhibitor"
    },
    {
      "id": "CHEMBL:348475",
      "type": "ChemicalCompound",
      "name": "Tariquidar",
      "mechanism": "P-glycoprotein inhibitor (third-generation)",
      "cross_references": {
        "chembl": "CHEMBL:348475"
      },
      "clinical_status": "Phase 2 completed, not advanced to approval"
    },
    {
      "id": "NCT:00001944",
      "type": "ClinicalTrial",
      "title": "P-Glycoprotein Antagonist XR9576 + Vinorelbine",
      "status": "COMPLETED",
      "phase": "Phase 1/2",
      "conditions": ["Breast Cancer", "Lung Cancer", "Ovarian Cancer"],
      "interventions": ["Vinorelbine", "XR9576 (P-gp inhibitor)"],
      "mechanism_tested": "ABCB1/P-gp inhibition",
      "evidence_level": "L4+"
    },
    {
      "id": "NCT:00001493",
      "type": "ClinicalTrial",
      "title": "MDR1 Gene Transduction + Paclitaxel/Doxorubicin for Stage 4 Breast Cancer",
      "status": "COMPLETED",
      "phase": "Phase 1/2",
      "conditions": ["Breast Neoplasms", "Neoplasm Metastasis"],
      "interventions": ["MDR1-transduced peripheral blood progenitor cells", "Doxorubicin", "Paclitaxel"],
      "mechanism_tested": "MDR1/ABCB1 gene therapy to protect normal cells",
      "evidence_level": "L4"
    },
    {
      "id": "NCT:05741372",
      "type": "ClinicalTrial",
      "title": "Transporter Profiling Study for P-gp and Other Drug Transporters",
      "status": "COMPLETED",
      "completion_date": "2024-12-18",
      "phase": "Pharmacokinetic Study",
      "conditions": ["Liver Cirrhosis"],
      "primary_outcomes": ["AUC and Cmax of digoxin (P-gp substrate)", "Transporter activity profiling"],
      "mechanism_tested": "P-gp functional activity measurement",
      "evidence_level": "L4"
    },
    {
      "id": "NCT:04216524",
      "type": "ClinicalTrial",
      "title": "Tagraxofusp + HCVAD/Mini-CVD + Venetoclax for BPDCN",
      "status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": ["Blastic Plasmacytoid Dendritic Cell Neoplasm"],
      "interventions": ["Doxorubicin", "Venetoclax", "Cyclophosphamide", "Cytarabine", "Vincristine"],
      "mechanism_tested": "BCL2 inhibition + doxorubicin combination",
      "primary_outcomes": ["Progression-free survival", "Overall response rate"],
      "evidence_level": "L4"
    },
    {
      "id": "NCT:00933985",
      "type": "ClinicalTrial",
      "title": "Obatoclax (Pan-BCL2 Inhibitor) + Vincristine/Doxorubicin in Pediatric Cancers",
      "status": "TERMINATED",
      "phase": "Phase 1",
      "completion_date": "2013-04",
      "conditions": ["Relapsed/Refractory Solid Tumors", "Leukemia"],
      "interventions": ["Obatoclax", "Doxorubicin", "Vincristine", "Dexrazoxane"],
      "mechanism_tested": "Pan-BCL2 family inhibition + doxorubicin",
      "termination_reason": "Not specified (likely toxicity or efficacy)",
      "evidence_level": "L3"
    },
    {
      "id": "NCT:03984448",
      "type": "ClinicalTrial",
      "title": "Venetoclax + Chemoimmunotherapy for MYC/BCL2 Double-Hit Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2/3",
      "conditions": ["Diffuse Large B-Cell Lymphoma", "Double-Expressor Lymphoma"],
      "interventions": ["Venetoclax", "Doxorubicin", "Cyclophosphamide", "Vincristine", "Rituximab"],
      "mechanism_tested": "BCL2 inhibition in BCL2-overexpressing tumors",
      "evidence_level": "L4"
    }
  ],
  "edges": [
    {
      "source": "CHEMBL:53463",
      "target": "HGNC:40",
      "relationship": "substrate_of_efflux_pump",
      "evidence": "P-glycoprotein actively effluxes doxorubicin, reducing intracellular concentration",
      "resistance_impact": "HIGH",
      "evidence_level": "L4+",
      "sources": ["UniProtKB:P08183", "NCT:00001944", "NCT:05741372"]
    },
    {
      "source": "CHEMBL:53463",
      "target": "HGNC:990",
      "relationship": "induces_apoptosis_via_mitochondrial_pathway",
      "evidence": "Doxorubicin causes DNA damage → p53 activation → BCL2 repression → apoptosis; BCL2 overexpression blocks this pathway",
      "resistance_impact": "HIGH",
      "evidence_level": "L4",
      "sources": ["UniProtKB:P10415", "NCT:04216524", "NCT:00933985"]
    },
    {
      "source": "CHEMBL:53463",
      "target": "HGNC:11998",
      "relationship": "activates_via_dna_damage",
      "evidence": "Doxorubicin-induced DNA damage activates p53-dependent apoptosis; TP53 mutations abolish this response",
      "resistance_impact": "HIGH",
      "evidence_level": "L3",
      "sources": ["UniProtKB:P04637", "STRING:9606.ENSP00000269305"]
    },
    {
      "source": "CHEMBL:53463",
      "target": "HGNC:11989",
      "relationship": "stabilizes_cleavage_complex",
      "evidence": "Doxorubicin stabilizes TOP2A-DNA cleavage complexes causing DNA double-strand breaks; TOP2A downregulation or mutations confer resistance",
      "resistance_impact": "MODERATE",
      "evidence_level": "L2-L3",
      "sources": ["UniProtKB:P11388", "NCT:00253500"]
    },
    {
      "source": "HGNC:40",
      "target": "CYP3A4",
      "relationship": "co-regulates_drug_metabolism",
      "evidence": "STRING interaction score 0.95; CYP3A metabolizes doxorubicin while P-gp effluxes both parent and metabolites",
      "functional_link": "Synergistic resistance",
      "string_score": 0.95,
      "sources": ["STRING:9606.ENSP00000478255"]
    },
    {
      "source": "HGNC:40",
      "target": "CYP3A5",
      "relationship": "co-regulates_drug_metabolism",
      "evidence": "STRING interaction score 0.92",
      "string_score": 0.92,
      "sources": ["STRING:9606.ENSP00000478255"]
    },
    {
      "source": "HGNC:990",
      "target": "HGNC:11998",
      "relationship": "transcriptionally_repressed_by",
      "evidence": "p53 transcriptionally represses BCL2; BCL2 overexpression can bypass p53-mediated apoptosis",
      "string_score": 0.999,
      "functional_implication": "TP53 mutations may lead to BCL2 upregulation → dual resistance mechanism",
      "sources": ["STRING:9606.ENSP00000269305", "STRING:9606.ENSP00000381185"]
    },
    {
      "source": "HGNC:990",
      "target": "BAX",
      "relationship": "inhibits_apoptosis",
      "evidence": "BCL2 prevents BAX-mediated mitochondrial outer membrane permeabilization",
      "string_score": 0.99,
      "sources": ["STRING:9606.ENSP00000381185"]
    },
    {
      "source": "HGNC:990",
      "target": "BAK1",
      "relationship": "inhibits_apoptosis",
      "string_score": 0.997,
      "sources": ["STRING:9606.ENSP00000381185"]
    },
    {
      "source": "HGNC:11998",
      "target": "MDM2",
      "relationship": "negative_feedback_regulation",
      "evidence": "MDM2 is E3 ubiquitin ligase that targets p53 for degradation; p53 transcriptionally activates MDM2",
      "string_score": 0.999,
      "therapeutic_target": "MDM2 inhibitors restore p53 function",
      "sources": ["STRING:9606.ENSP00000269305", "NCT:03041688"]
    },
    {
      "source": "HGNC:11998",
      "target": "ATM",
      "relationship": "activated_by_dna_damage_sensor",
      "evidence": "ATM phosphorylates p53 in response to DNA double-strand breaks",
      "string_score": 0.995,
      "sources": ["STRING:9606.ENSP00000269305"]
    },
    {
      "source": "HGNC:11989",
      "target": "CDK1",
      "relationship": "cell_cycle_regulation",
      "evidence": "TOP2A activity is cell cycle-dependent; CDK1 regulates G2/M transition",
      "string_score": 0.999,
      "functional_implication": "Cell cycle arrest may reduce TOP2A-mediated DNA damage from doxorubicin",
      "sources": ["STRING:9606.ENSP00000411532"]
    },
    {
      "source": "HGNC:11989",
      "target": "CCNB1",
      "relationship": "cell_cycle_regulation",
      "string_score": 0.989,
      "sources": ["STRING:9606.ENSP00000411532"]
    },
    {
      "source": "CHEMBL:3137309",
      "target": "HGNC:990",
      "relationship": "inhibits",
      "evidence": "Venetoclax is selective BCL2 inhibitor; FDA-approved for CLL/AML",
      "clinical_validation": "Completed Phase 3 trials; FDA approved",
      "sources": ["IUPHAR:8318", "NCT:04216524", "NCT:03984448"]
    },
    {
      "source": "CHEMBL:6966",
      "target": "HGNC:40",
      "relationship": "inhibits",
      "evidence": "Verapamil is first-generation P-gp inhibitor but limited by cardiac toxicity",
      "generation": "First-generation",
      "limitation": "Cardiac side effects",
      "sources": ["IUPHAR:2406"]
    },
    {
      "source": "CHEMBL:348475",
      "target": "HGNC:40",
      "relationship": "inhibits",
      "evidence": "Tariquidar is third-generation P-gp inhibitor; completed Phase 2 but not advanced",
      "generation": "Third-generation",
      "clinical_status": "Phase 2 completed, not approved",
      "sources": ["CHEMBL:348475", "NCT:00001944"]
    },
    {
      "source": "NCT:00001944",
      "target": "HGNC:40",
      "relationship": "validates_mechanism",
      "evidence": "Completed clinical trial testing P-gp inhibitor XR9576 (tariquidar analog) with vinorelbine",
      "trial_status": "COMPLETED",
      "evidence_strength": "L4+"
    },
    {
      "source": "NCT:00001493",
      "target": "HGNC:40",
      "relationship": "validates_mechanism",
      "evidence": "MDR1 gene transduction protected hematopoietic cells from doxorubicin/paclitaxel toxicity, enabling dose escalation",
      "trial_status": "COMPLETED",
      "evidence_strength": "L4"
    },
    {
      "source": "NCT:05741372",
      "target": "HGNC:40",
      "relationship": "measures_functional_activity",
      "evidence": "Transporter profiling study measured P-gp activity via digoxin PK in liver cirrhosis patients",
      "trial_status": "COMPLETED (2024-12-18)",
      "evidence_strength": "L4"
    },
    {
      "source": "NCT:04216524",
      "target": "HGNC:990",
      "relationship": "validates_mechanism",
      "evidence": "Active Phase 2 trial combining venetoclax (BCL2 inhibitor) with doxorubicin-containing HCVAD regimen",
      "trial_status": "RECRUITING",
      "evidence_strength": "L4"
    },
    {
      "source": "NCT:00933985",
      "target": "HGNC:990",
      "relationship": "validates_mechanism",
      "evidence": "Phase 1 trial of obatoclax (pan-BCL2 inhibitor) + doxorubicin in pediatric cancers; terminated early",
      "trial_status": "TERMINATED (2013)",
      "evidence_strength": "L3"
    },
    {
      "source": "NCT:03984448",
      "target": "HGNC:990",
      "relationship": "validates_mechanism",
      "evidence": "Active Phase 2/3 trial of venetoclax + R-CHOP (doxorubicin-containing) for MYC/BCL2 double-hit lymphomas",
      "trial_status": "ACTIVE_NOT_RECRUITING",
      "evidence_strength": "L4"
    }
  ],
  "resistance_pathways": {
    "drug_efflux": {
      "key_proteins": ["ABCB1", "CYP3A4", "CYP3A5", "SLCO1B1", "NR1I2"],
      "mechanism": "Active export of doxorubicin and metabolites reduces intracellular concentration",
      "clinical_validation": "3 completed trials (NCT:00001944, NCT:00001493, NCT:05741372)",
      "evidence_grade": "L4+",
      "correlation": "STRONG"
    },
    "apoptosis_evasion": {
      "key_proteins": ["BCL2", "BAX", "BAK1", "BIM", "PUMA", "NOXA", "TP53"],
      "mechanism": "BCL2 overexpression prevents mitochondrial outer membrane permeabilization and caspase activation",
      "clinical_validation": "10+ trials combining venetoclax with doxorubicin-based regimens",
      "evidence_grade": "L4",
      "correlation": "STRONG"
    },
    "p53_loss": {
      "key_proteins": ["TP53", "MDM2", "ATM", "RPA1", "SIRT1"],
      "mechanism": "TP53 mutations abolish p53-mediated apoptosis and cell cycle arrest in response to DNA damage",
      "clinical_validation": "Biomarker trials stratifying by p53 status; Wee1 inhibitor trials for p53-mutant tumors",
      "evidence_grade": "L3",
      "correlation": "MODERATE"
    },
    "topoisomerase_alterations": {
      "key_proteins": ["TOP2A", "CDK1", "CCNB1", "CDC20"],
      "mechanism": "TOP2A downregulation or mutations reduce doxorubicin target availability",
      "clinical_validation": "Limited; 1 completed biomarker trial (epirubicin response prediction)",
      "evidence_grade": "L2-L3",
      "correlation": "WEAK-MODERATE"
    }
  },
  "clinical_outcome_summary": {
    "total_trials_analyzed": 40,
    "p_gp_trials": 3,
    "bcl2_trials": 10,
    "tp53_trials": 5,
    "top2a_trials": 2,
    "platinum_resistant_ovarian_cancer_trials": 18,
    "key_findings": [
      "ABCB1/P-gp: Strong preclinical-to-clinical correlation (L4+) with completed PK and gene therapy trials",
      "BCL2: Strong correlation (L4) with 10+ combination trials and FDA-approved venetoclax",
      "TP53: Moderate correlation (L3) with biomarker-driven trials but no large outcome studies",
      "TOP2A: Weak-to-moderate correlation (L2-L3) with limited direct clinical validation"
    ],
    "overall_confidence": "HIGH",
    "median_evidence_grade": "L3-L4"
  }
}
